Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

BACKGROUND: Antiangiogenic agents have improved the prognosis of non-squamous non-small–cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor’s characteristics or comorbidities. Much less information is available a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergnenègre, Alain, Basse, Victor, Le Garff, Gwenaelle, Bylicki, Olivier, Dubos-Arvis, Catherine, Comet, Bénédicte, Marcq, Marie, Le Treut, Jacques, Auliac, Jean-Bernard, Madroszyk, Anne, Fraboulet, Gislaine, Crequit, Jacky, Thomas, Pascal, Paleiron, Nicolas, Monnet, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938186/
https://www.ncbi.nlm.nih.gov/pubmed/31920391
http://dx.doi.org/10.2147/CMAR.S219984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938186/
https://www.ncbi.nlm.nih.gov/pubmed/31920391
http://dx.doi.org/10.2147/CMAR.S219984

Ejemplares similares